Advertisement

Reste-t-il une place pour ľimmunothérapie dans la prise en charge des stades métastasiques?

  • Sylvie Négrier
Chapter
  • 331 Downloads
Part of the Oncologie pratique book series (ONCOLPRAT)

Abstrait

Pendant environ 20 ans, ľimmunothérapie a représenté la seule option thérapeutique pour les patients porteurs de cancer du rein métastatique, et il y a différentes raisons pour expliquer cette particularité:
  • - la première est à ľévidence la résistance spontanée des tumeurs du rein pour la chimiothérapie (1, 2);

  • - la deuxième raison est fondée sur des observations cliniques et des études mettant en avant le rôle du système immunitaire dans le contrôle tumoral.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Lilleby W, Fossa SD (2005) Chemotherapy in metastatic renal cell cancer. World J Urol 23: 175–9PubMedCrossRefGoogle Scholar
  2. 2.
    Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22: 42–60PubMedGoogle Scholar
  3. 3.
    Chvetzoff G, Tannock IF (2003) Placebo effects in oncology. J Natl Cancer Inst 95: 19–29PubMedCrossRefGoogle Scholar
  4. 4.
    Gleave ME, Elhilali M, Fradet Y et al. (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338: 1265–71PubMedCrossRefGoogle Scholar
  5. 5.
    Oliver RT (1998) Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now? Br J Cancer 77: 1318–20PubMedGoogle Scholar
  6. 6.
    Rosenberg SA, Lotze MT, Muul LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lympholine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–97PubMedGoogle Scholar
  7. 7.
    Childs R, Chernoff A, Contentin N et al. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750–8PubMedCrossRefGoogle Scholar
  8. 8.
    Law TM, Motzer RJ, Mazumdar M et al. (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76: 824–32PubMedCrossRefGoogle Scholar
  9. 9.
    Rosenberg SA, Lotze MT, Yang JC et al. (1993) Prospective randomized trial of highdose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85: 622–32PubMedCrossRefGoogle Scholar
  10. 10.
    Weiss GR, Margolin KA, Aronson FR et al. (1992) A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10: 275–81PubMedGoogle Scholar
  11. 11.
    West WH, Tauer KW, Yannelli JR et al. (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905PubMedGoogle Scholar
  12. 12.
    Sleijfer DT, Janssen RA, Willemse PH et al. (1990) Low-dose regimen of interleukin-2 for metastatic renal carcinoma. Lancet 335: 1522–3PubMedCrossRefGoogle Scholar
  13. 13.
    Atzpodien J, Korfer A, Franks CR et al. (1990) Home therapy with recombinant interleukin-2 and interferon alpha 2b in advanced human malignancies. Lancet 335: 1509–12PubMedCrossRefGoogle Scholar
  14. 14.
    Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353: 14–7CrossRefGoogle Scholar
  15. 15.
    Pyrhonen S, Salminen E, Ruutu M et al. (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859–67PubMedGoogle Scholar
  16. 16.
    Ravaud A, Audhuy B, Gomez F et al. (1998) Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial Groupe Français ďImmunothérapie. J Clin Oncol 16: 2728–32PubMedGoogle Scholar
  17. 17.
    Négrier S, Escudier B, Lasset C et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français ďImmunothérapie. N Engl J Med 338: 1272–8PubMedCrossRefGoogle Scholar
  18. 18.
    Coppin C, Porzsolt F, Awa A et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev CD001425Google Scholar
  19. 19.
    Négrier S, Escudier B, Gomez F et al. (2002) Pronostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français ďImmunothérapie. Ann Oncol 13: 1460–8PubMedCrossRefGoogle Scholar
  20. 20.
    Négrier S, Pérol D, Ravaud A et al. (2007) Medroxyprogesterone, Interferon alpha 2a, Interleukin 2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. Results of a randomized controlled trial. Cancer (in press)Google Scholar
  21. 21.
    Négrier S, Pérol D, Ravaud A et al. (2006) In intravenous (iv) IL2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (MRCC) receiving a combination of IL2 and alpha Interferon (IFN)? Results of the prospective randomized PERCY Duo trial. ASCO Annual Meeting Proceeding, J Clin Oncol 24 (18s (June 20 Suppl)), Abstr 4536Google Scholar
  22. 22.
    Gollob JA, Rathmell WK, Richmond TM et al. (2007) Phase II trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25: 3288–95PubMedCrossRefGoogle Scholar
  23. 23.
    Ryan CW, Goldman BH, Lara PN Jr. et al. (2007) Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25: 3296–301PubMedCrossRefGoogle Scholar
  24. 24.
    Hudes G, Carducci M, Tomczak P et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271–81PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2008

Authors and Affiliations

  • Sylvie Négrier
    • 1
  1. 1.Medical Oncology Dept et Inserm unité 590Université de Lyon et centre Léon BérardLyon Cedex 08France

Personalised recommendations